Inventor · disambiguated record
Daniel A. Vallera
Also filed as: VALLERA DANIEL A · VALLERA DANIEL ATTILIO · Vallera Daniel
15 granted patents·11 pending applications·252 citations·filing 1986–2025
93Inventor score
Files withUNIV MINNESOTA18VALLERA DANIEL A4OHLFEST JOHN R1UAB RESEARCH FOUNDATION1UNIV MINNESOTA A MINNESOTA COR1
Top patents by PatentIndex Score
26 records- 0193US11098109B2Single-chain variable fragment anti-CD133 antibodies and uses thereofUNIV MINNESOTA·Filed 2017·Granted Aug 24, 2021·7 cites·13 claims
- 0291US9624303B2Single-chain variable fragment anti-CD133 antibodies and uses thereofUNIV MINNESOTA·Filed 2016·Granted Apr 18, 2017·7 cites·3 claims
- 0391US6001329ARadiolabeled fusion toxins for cancer therapyUAB RESEARCH FOUNDATION·Filed 1997·Granted Dec 14, 1999·91 cites·11 claims
- 0490US9249225B2Single chain variable fragment anti-CD133 antibodies and uses thereofOHLFEST JOHN R·Filed 2010·Granted Feb 2, 2016·13 cites·18 claims
- 0584US6492498B1Multimeric immunotoxinsUNIV MINNESOTA·Filed 1999·Granted Dec 10, 2002·45 cites·28 claims
- 0683US9155798B2Receptor-targeting reagents containing epidermal factor receptor-binding agents and IL-13 receptor-binding agents or IL-4 receptor-binding agentsVALLERA DANIEL A·Filed 2008·Granted Oct 13, 2015·4 cites·15 claims
- 0783US7101542B1Cell-mediated targeting of toxins to pathogenic cellsVALLERA DANIEL A·Filed 2000·Granted Sep 5, 2006·11 cites·25 claims
- 0881US4831122ARadioimmunotoxinsUNIV MINNESOTA·Filed 1986·Granted May 16, 1989·62 cites·6 claims
- 0980US11098101B2Therapeutic compounds and methodsUNIV MINNESOTA·Filed 2019·Granted Aug 24, 2021·1 cites·10 claims
- 1079US6846484B2DTAT fusion toxinUNIV MINNESOTA·Filed 2001·Granted Jan 25, 2005·7 cites·24 claims
- 1176US9371386B2Methods and compositions for bi-specific targeting of CD19/CD22VALLERA DANIEL A·Filed 2010·Granted Jun 21, 2016·3 cites·13 claims
- 1275US11098100B2Therapeutic compounds and methodsUNIV MINNESOTA·Filed 2016·Granted Aug 24, 2021·1 cites·19 claims
- 1371US12269887B2Anti-canine CD16 polypeptides, anti-canine CD64 polypeptides, compositions including same, and methods of usingUNIV MINNESOTA·Filed 2023·Granted Apr 8, 2025·0 cites·20 claims
- 1461US12319737B2NK engager molecules and methods of use thereofUNIV MINNESOTA·Filed 2019·Granted Jun 3, 2025·0 cites·14 claims
- 1558US2025304701A1Nk engager molecules and methods of use thereofUNIV MINNESOTA·Filed 2025·Application pending·0 cites
- 1656US2019388521A1Reduction of egfr therapeutic toxicityUNIV MINNESOTA·Filed 2019·Application pending·0 cites
- 1753US2005245448A1DTAT fusion toxinUNIV MINNESOTA A MINNESOTA COR·Filed 2005·Application pending·0 cites
- 1852US2017106059A1Reduction of egfr therapeutic toxicityUNIV MINNESOTA·Filed 2016·Application pending·0 cites
- 1952US2016000868A1Receptor-targeting reagentsUNIV MINNESOTA·Filed 2015·Application pending·0 cites
- 2051US11208634B2Deimmunized therapeutic compositions and methodsUNIV MINNESOTA·Filed 2016·Granted Dec 28, 2021·0 cites·22 claims
- 2151US2002048579A1Ex vivo treatment of allogeneic and xenogeneic donor T-cells containing compositions (bone marrow) using gp39 antagonists and use thereofUNIV MINNESOTA·Filed 2001·Application pending·0 cites
- 2248US2022324972A1Immunotherapy compounds and methodsUNIV MINNESOTA·Filed 2020·Application pending·0 cites
- 2346US2002048550A1Radiolabeled immunotoxinsFiled 2001·Application pending·0 cites
- 2444US2017137513A1Methods and compositions for bi-specific targeting of cd19/cd22VALLERA DANIEL A·Filed 2016·Application pending·0 cites
- 2544US2002022020A1Ex vivo treatment of allogeneic and xenogeneic donor T-cells containing compositions (bone marrow) using gp39 antagonists and use thereofUNIV MINNESOTA·Filed 2001·Application pending·0 cites
- 2644US2022363737A1Nk engager compounds that bind viral antigens and methods of useUNIV MINNESOTA·Filed 2020·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →